Dyspareunia and vaginal dryness after breast cancer treatment

Sexuality, Reproduction and Menopause

Volumn 6, Issue 3, 2008, Pages 18-22

  Wiggins, Doreen Leyden ^a   Dizon, Don S ^b  

^a Program in Women's Oncology   (United States)

^b Department of Obstetrics and Gynecology and Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; GABAPENTIN; HORMONE; LIDOCAINE; LUBRICATING AGENT; PILOCARPINE; POLYCARBOPHIL; RALOXIFENE; TAMOXIFEN;

AMENORRHEA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RISK; CLINICAL TRIAL; CREAM; DRUG DOSE COMPARISON; DRUG EFFICACY; DYSPAREUNIA; ENDOMETRIUM HYPERPLASIA; ESTROGEN BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; INFERTILITY; INFLAMMATION; LOW DRUG DOSE; LUBRICATION; MALIGNANT NEOPLASTIC DISEASE; MENOPAUSAL SYNDROME; MUCOSA INFLAMMATION; NONHUMAN; OLIGOMENORRHEA; POSTMENOPAUSE; PRIORITY JOURNAL; RISK REDUCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN TOXICITY; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA DISEASE; VAGINAL BURNING SENSATION; VAGINAL DRYNESS; VAGINITIS; VULVODYNIA;

EID: 57749197572     PISSN: 15462501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. American Cancer Society. Cancer facts and figures 2007. Available at: www.cancer.org. Accessed June 25, 2008.
2. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol. 1998;16:501-514.
3. Broeckel JA, Thors CL, Jacobsen PB, Small M, Cox CE. Sexual functioning in long-term breast cancer survivors treated with adjuvant chemotherapy. Breast Cancer Res Treat. 2002;75:241-248.
4. Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA. 1983;249:2195-2198.
5. Krychman ML, Carter J, Aghajanian CA, Dizon DS, Castiel M. Chemotherapy-induced dyspareunia: a case study of vaginal mucositis and pegylated liposomal doxorubicin injection in advanced stage ovarian carcinoma. Gynecol Oncol. 2004;93:561-563.
6. Decensi A, Fontana V, Bruno S, Gustavino C, Gatteschi B, Costa A. Effect of tamoxifen on endometrial proliferation. J Clin Oncol. 1996;14:434-440.
7. Cohen I, Rosen DJ, Altaras M, Beyth Y, Shapira J, Yigael D. Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth. Br J Cancer. 1994;63:620-621.
8. Tajima C, Takeda B, Tamaki Y. Effect of tamoxifen on cervical mucus, vaginal smear and endometrial findings. Fertil Steril. 1979;24:23-26.
9. National Cancer Institute. FDA approval for raloxifene hydrochloride. Available at: www.cancer.gov/cancertopics/druginfo/ fda-raloxifene-hydrochloride. Accessed June 25, 2008.
10. Plouffe L Jr. Selective estrogen receptor modulators (SERMs) in clinical practice. J Soc Gynecol Investig. 2000;7(1 suppl):S38-S46.
11. Davies GC, Huster WJ, Lu Y, Plouffe L Jr, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol. 1999;93:558-565.
12. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647.
13. Parsons A, Merritt D, Rosen A, Heath H 3rd, Siddhanti S, Plouffe L Jr; Study Groups on the Effects of Raloxifene HCI With Low-Dose Premarin Vaginal Cream. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol. 2003;101:346-352.
14. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol. 2004;22:4261-4271.
15. Wiegerink MA, Poortman J, Agema AR, Thijssen JH. Estrogen receptors in human vaginal tissue. Maturitas. 1980;2:59-67.
16. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000;61:3090-3096.
17. Melis GB, Ibba MT, Steri B, Kotsonis P, Matta V, Paoletti AM. Role of pH as a regulator of vaginal physiological environment [in Italian]. Minerva Ginecol. 2000;52:111-121.
18. Nilsson K, Risberg B, Heimer G. The vaginal epithelium in the postmenopause-cytology, histology and pH as methods of assessment. Maturitas. 1995;21:51-56.
19. Speer JJ, Hillenberg B, Sugrue DP, et al. Study of sexual functioning determinants in breast cancer survivors. Breast J. 2005; 11:440-447.
20. Andersen BL, Carpenter KM, Yang HC, Shapiro CL. Sexual well-being among partnered women with breast cancer recurrence. J Clin Oncol. 2007;25:3151-3157.
21. Adriaens E, Remon JP. Mucosal irritation potential of personal lubricants relates to product osmolality as detected by the slug mucosal irritation assay. Sex Transm Dis. 2008;35:512-516.
22. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril. 1994;61:178-180.
23. Hubbard GB, Carey KD, Levine H, Bachmann GA. Evaluation of a vaginal moisturizer in baboons with decreasing ovarian function. Lab Anim Sci. 1997;47:36-39.
24. Gelfand MM, Wendman E. Treating vaginal dryness in breast cancer patients: results of applying a polycarbophil moisturizing gel. J Womens Health. 1994;3:427-434.
25. van der Laak JA, de Bie LM, de Leeuw H, de Wilde PC, Hanselaar AGl. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerized cytometry. J Clin Pathol. 2002;55:446-451
26. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23:259-263.
27. Lorinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil based vaginal moisturizer in women with breast cancer. J Clin Oncol. 1997;15:969-973.
28. Vagisil Women's Health Center. Available at: www.vagisil.com. Accessed June 25, 2008.
29. Yes Web site. Available at: www.yesyesyes.org. Accessed June 25, 2008.
30. Astroglide Web site. Available at: www.astroglide.com. Accessed June 25, 2008.
31. Le Veque FG, Hendrix S. Oral pilocarpine to treat vaginal xerosis associated with chemotherapy-induced amenorrhea in premenopausal women. Paper presented at: 2004 American Society of Clinical Oncology Annual Meeting; June 5-8, 2004; New Orleans, Louisianna. J Clin Oncol. 2004;22 (suppl):14S. Abstract 8099.
32. Ferguson DM, Steidle CP, Singh GS, Alexander JS, Weihmiller MK, Crosby MG. Randomized, placebo-controlled, double blind, crossover design trial of the efficacy and safety of Zestra for Women in women with and without female sexual arousal disorder. J Sex Marital Ther. 2003;29(suppl):33-44.
33. Zolnoun DA, Hartmann KE, Steege JF. Overnight 5% lidocaine ointment for treatment of vulvar vestibulitis. Obstet Gynecol. 2003;102:84-87.
34. Boardman LA, Cooper AS. Topical 2%-6% gabapentin in the treatment of vulvodynia. Presented at: The XIX World Congress of the International Society for the Study of Vulvovaginal Disease; July 2007; Vancouver, British Columbia, Canada.
35. Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas. 2003;45:29-38.
36. Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist. 2008;13:222-231.
37. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause. 2000;7:156-161.
38. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005;8:83-92.
39. Smith P, Heimer G, Lindskog M, Ulmsten U. Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas. 1993;16:145-154.
40. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006;17:584-587.
41. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol. 2008;111:67-76.